Stifel Maintains Buy on Incyte, Raises Price Target to $157
Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.
Stocks · News reference
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123
JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield
iShares U.S. Healthcare ETF (IYH) outperformed its global counterpart (IXJ) with 28.8% one-year returns versus 22.5%, while IXJ offers higher dividend yield at 1.4%. Both funds have nearly identical expense ratios (0.37-0.38%) and low volatility, with choice depending on whether investors prefer domestic or international healthcare exposure.